Curcumin nano-prodrug induces multi-phase cell cycle arrest in colorectal cancer through suppression of CDKs and specific down-regulation of PLK1
Authors:
- Dong XuDXDong Xu
- Xingzhi FengXFXingzhi Feng
- Yuxin WanYWYuxin Wan
- Lanlan YangLYLanlan Yang
- Qianling GaoQGQianling Gao
- Zihuan YangZYZihuan Yang
- Chang DuCDChang Du
Open Access
- 1 January 2023
- journal article
- research article
- Published by KEAI Publishing in Smart Materials in Medicine
- Vol. 4, 648-660
Abstract
No abstract availableFunding Information
- Science and Technology Planning Project of Guangdong Province (2020A1414010034)
- Higher Education Discipline Innovation Project (B13039)
- National Natural Science Foundation of China (81702330)
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China (2017YFC1105000)
- Natural Science Foundation of Guangdong Province (2021A1515011400)
This publication has 49 references indexed in Scilit:
- PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryAdvanced Drug Delivery Reviews, 2016
- Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2International Journal of Molecular Sciences, 2015
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyBlood, 2014
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyLeukemia, 2014
- Antagonism between curcumin and the topoisomerase II inhibitor etoposideCancer Biology & Therapy, 2012
- The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulationBiomaterials, 2010
- Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to MitosisDevelopmental Cell, 2010
- Targeting Polo-like Kinase in Cancer TherapyClinical Cancer Research, 2010
- Validation Studies of the Site-Directed Docking Program LibDockJournal of Chemical Information and Modeling, 2007
- DrugBank: a comprehensive resource for in silico drug discovery and explorationNucleic Acids Research, 2006